- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Squamous cell carcinoma (SCC)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 868KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 151KB)
Pembrolizumab – November 2023
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
1 March 2024